ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.
With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
We are a multi-disciplinary team of scientists, technologists and business leaders, committed to providing the framework required for effective and efficient drug development. Collaboration is the key to making this happen; each member of the ValiRx team plays a vital role in the strength and success of our programmes, which are focused on achieving the best outcomes for patients, at the lowest cost, in the shortest timeframe.
We connect diverse disciplines across scientific, technical and commercial domains, with the promise of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.
Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.